BR0214564A - Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos - Google Patents
Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicosInfo
- Publication number
- BR0214564A BR0214564A BR0214564-2A BR0214564A BR0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A BR 0214564 A BR0214564 A BR 0214564A
- Authority
- BR
- Brazil
- Prior art keywords
- antineoplastic agents
- fpt inhibitor
- treatment processes
- cancer treatment
- medicament
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33441101P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/037954 WO2003047697A2 (en) | 2001-11-30 | 2002-11-25 | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214564A true BR0214564A (pt) | 2004-11-09 |
Family
ID=23307076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214564-2A BR0214564A (pt) | 2001-11-30 | 2002-11-25 | Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20030185831A1 (enExample) |
| EP (1) | EP1448268A2 (enExample) |
| JP (1) | JP2005511663A (enExample) |
| CN (2) | CN101181269A (enExample) |
| AU (1) | AU2002352941A1 (enExample) |
| BR (1) | BR0214564A (enExample) |
| CA (1) | CA2468839A1 (enExample) |
| HU (1) | HUP0402401A2 (enExample) |
| MX (1) | MXPA04005207A (enExample) |
| NO (1) | NO20042730L (enExample) |
| NZ (1) | NZ532562A (enExample) |
| WO (1) | WO2003047697A2 (enExample) |
| ZA (1) | ZA200403737B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009088A1 (en) * | 2002-07-24 | 2004-01-29 | Novartis Ag | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| WO2005046691A1 (en) * | 2003-11-06 | 2005-05-26 | Schering Corporation | Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| WO2005082397A1 (en) * | 2004-02-26 | 2005-09-09 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| JP2009511450A (ja) * | 2005-10-07 | 2009-03-19 | ノバルティス アクチエンゲゼルシャフト | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
| JP2010507662A (ja) * | 2006-10-25 | 2010-03-11 | シェーリング コーポレイション | 癌の処置のための不連続方法 |
| EP2088862A4 (en) * | 2006-11-28 | 2009-12-02 | Smithkline Beecham Cork Ltd | METHOD OF TREATING CANCER |
| JP2025538184A (ja) | 2022-11-09 | 2025-11-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 先天性の抗腫瘍免疫を誘発する免疫刺激要因としてのトール様受容体７アゴニスト |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874442A (en) * | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| NZ504928A (en) * | 1997-12-22 | 2004-12-24 | Schering Corp | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| PT1255537E (pt) * | 2000-02-04 | 2006-09-29 | Janssen Pharmaceutica Nv | Inibidores da proteina farnesil transferase para tratar cancro da mama |
| ATE375794T1 (de) * | 2000-02-24 | 2007-11-15 | Janssen Pharmaceutica Nv | Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs |
| AU2001244166A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| US20030181473A1 (en) * | 2000-02-29 | 2003-09-25 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with taxane compounds |
| AR033680A1 (es) * | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| HK1052870A1 (zh) * | 2000-10-05 | 2003-10-03 | Q. Daley George | 诱导癌细胞死亡和肿瘤消退的方法 |
-
2002
- 2002-11-25 US US10/303,259 patent/US20030185831A1/en not_active Abandoned
- 2002-11-25 JP JP2003548949A patent/JP2005511663A/ja not_active Withdrawn
- 2002-11-25 EP EP02789901A patent/EP1448268A2/en not_active Withdrawn
- 2002-11-25 HU HU0402401A patent/HUP0402401A2/hu unknown
- 2002-11-25 CN CNA2007101860344A patent/CN101181269A/zh active Pending
- 2002-11-25 AU AU2002352941A patent/AU2002352941A1/en not_active Abandoned
- 2002-11-25 BR BR0214564-2A patent/BR0214564A/pt not_active IP Right Cessation
- 2002-11-25 CA CA002468839A patent/CA2468839A1/en not_active Abandoned
- 2002-11-25 MX MXPA04005207A patent/MXPA04005207A/es unknown
- 2002-11-25 WO PCT/US2002/037954 patent/WO2003047697A2/en not_active Ceased
- 2002-11-25 CN CNA028239202A patent/CN1617755A/zh active Pending
- 2002-11-25 NZ NZ532562A patent/NZ532562A/en unknown
-
2004
- 2004-05-14 ZA ZA200403737A patent/ZA200403737B/en unknown
- 2004-06-29 NO NO20042730A patent/NO20042730L/no not_active Application Discontinuation
-
2006
- 2006-04-03 US US11/396,892 patent/US20060183765A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ532562A (en) | 2007-02-23 |
| MXPA04005207A (es) | 2004-08-19 |
| EP1448268A2 (en) | 2004-08-25 |
| CA2468839A1 (en) | 2003-06-12 |
| US20030185831A1 (en) | 2003-10-02 |
| CN1617755A (zh) | 2005-05-18 |
| AU2002352941A1 (en) | 2003-06-17 |
| ZA200403737B (en) | 2005-05-23 |
| NO20042730L (no) | 2004-06-29 |
| WO2003047697A2 (en) | 2003-06-12 |
| CN101181269A (zh) | 2008-05-21 |
| WO2003047697A3 (en) | 2003-10-30 |
| HUP0402401A2 (hu) | 2005-03-29 |
| JP2005511663A (ja) | 2005-04-28 |
| US20060183765A1 (en) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03008623A (es) | Combinacion farmaceutica para el tratamiento del cancer. | |
| AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
| BR9906581A (pt) | Processo para administração de taxano encapsulado em lipossomos | |
| BR0208373A (pt) | Inibidores da tirosina cinase | |
| BR0312464A (pt) | Inibidores de tirosina quinases | |
| TR200002243T2 (tr) | Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı. | |
| PA8479201A1 (es) | Derivados del acido hidroxi-pipecolato hidroxamico | |
| MXPA04005425A (es) | Uso de inhibidores de farnesil proteina transferasa y por lo menos dos agentes antineoplasicos en el tratamiento de cancer. | |
| MXPA04001876A (es) | Uso de fucanos en el tratamiento de adhesiones, artritis y psoriasis. | |
| WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
| BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
| WO2002102306A3 (en) | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy | |
| BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
| BR0108728A (pt) | Combinação farmacêutica terapêutica, e, método para tratar um c ncer. | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| BR0214564A (pt) | Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos | |
| BR0209128A (pt) | Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
| PT1085884E (pt) | Combinacao de compostos seleniferos com gemcitabina ou mitomicina c | |
| WO2004012746A3 (en) | New uses for inhibitors of inosine monophosphate dehydrogenase | |
| BRPI0413410A (pt) | co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer | |
| BR9814419A (pt) | "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas" | |
| BR9911559A (pt) | Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo. | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE A 8.6 DA RPI 2108 DE 31/05/2011. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/4545 (2006.01), A61P 35/00 (2006.01) |